Q-omics provides the consensus-scored CREB3L2 profile across patient tissues and cancer cell-line models. CREB3L2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CREB3L2 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CREB3L2 RNA expression shows 19,919 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, THCA, and KIRP as cancer lineages where CREB3L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CREB3L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CREB3L2 survival associations across molecular data types. CREB3L2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CREB3L2 RNA expression–survival associations across cancer types. High CREB3L2 expression shows unfavorable associations in MESO, BLCA, LGG, LUSC and STAD, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify MESO as the clearest survival context for CREB3L2 RNA expression.
This table summarizes CREB3L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CREB3L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CREB3L2 shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, LUAD, HNSC and COAD. The THCA box plot shows higher CREB3L2 RNA expression in normal versus tumor tissue (log2 FC = −1.464, t-test p < 0.001).
This table shows molecular features associated with CREB3L2 in patient tissues and cancer cell lines. In patient samples, CREB3L2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CREB3L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and CNS.
